171 related articles for article (PubMed ID: 20584905)
21. K
Bientinesi R; Mancuso C; Martire M; Bassi PF; Sacco E; Currò D
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):127-137. PubMed ID: 27761601
[TBL] [Abstract][Full Text] [Related]
22. Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP
Ambrosino P; Freri E; Castellotti B; Soldovieri MV; Mosca I; Manocchio L; Gellera C; Canafoglia L; Franceschetti S; Salis B; Iraci N; Miceli F; Ragona F; Granata T; DiFrancesco JC; Taglialatela M
Mol Neurobiol; 2018 Aug; 55(8):7009-7024. PubMed ID: 29383681
[TBL] [Abstract][Full Text] [Related]
23. The Role of the Carboxyl Terminus Helix C-D Linker in Regulating KCNQ3 K+ Current Amplitudes by Controlling Channel Trafficking.
Choveau FS; Zhang J; Bierbower SM; Sharma R; Shapiro MS
PLoS One; 2015; 10(12):e0145367. PubMed ID: 26692086
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay.
Li Q; Rottländer M; Xu M; Christoffersen CT; Frederiksen K; Wang MW; Jensen HS
Anal Biochem; 2011 Nov; 418(1):66-72. PubMed ID: 21782781
[TBL] [Abstract][Full Text] [Related]
25. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
[TBL] [Abstract][Full Text] [Related]
26. Retigabine holds KV7 channels open and stabilizes the resting potential.
Corbin-Leftwich A; Mossadeq SM; Ha J; Ruchala I; Le AH; Villalba-Galea CA
J Gen Physiol; 2016 Mar; 147(3):229-41. PubMed ID: 26880756
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic potential of neuronal KCNQ channel modulators.
Gribkoff VK
Expert Opin Ther Targets; 2003 Dec; 7(6):737-48. PubMed ID: 14640909
[TBL] [Abstract][Full Text] [Related]
28. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of ICA-27243 on cloned K(V)7 channels.
Blom SM; Schmitt N; Jensen HS
Pharmacology; 2010; 86(3):174-81. PubMed ID: 20714208
[TBL] [Abstract][Full Text] [Related]
30. Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.
Osuma AT; Xu X; Wang Z; Van Camp JA; Freiberg GM
Bioorg Med Chem Lett; 2019 Oct; 29(19):126603. PubMed ID: 31416667
[TBL] [Abstract][Full Text] [Related]
31. Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence/fluorescence resonance energy transfer and patch clamp analysis.
Bal M; Zhang J; Zaika O; Hernandez CC; Shapiro MS
J Biol Chem; 2008 Nov; 283(45):30668-76. PubMed ID: 18786918
[TBL] [Abstract][Full Text] [Related]
32. From pan-reactive KV7 channel opener to subtype selective opener/inhibitor by addition of a methyl group.
Blom SM; Rottländer M; Kehler J; Bundgaard C; Schmitt N; Jensen HS
PLoS One; 2014; 9(6):e100209. PubMed ID: 24956197
[TBL] [Abstract][Full Text] [Related]
33. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.
Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794
[TBL] [Abstract][Full Text] [Related]
34. Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels.
Punke MA; Friederich P
Anesth Analg; 2007 May; 104(5):1256-64, tables of contents. PubMed ID: 17456683
[TBL] [Abstract][Full Text] [Related]
35. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
Dost R; Rostock A; Rundfeldt C
Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
[TBL] [Abstract][Full Text] [Related]
36. A possible link between KCNQ2- and STXBP1-related encephalopathies: STXBP1 reduces the inhibitory impact of syntaxin-1A on M current.
Devaux J; Dhifallah S; De Maria M; Stuart-Lopez G; Becq H; Milh M; Molinari F; Aniksztejn L
Epilepsia; 2017 Dec; 58(12):2073-2084. PubMed ID: 29067685
[TBL] [Abstract][Full Text] [Related]
37. Kv7 (KCNQ) channel openers induce hypothermia in the mouse.
Kristensen LV; Sandager-Nielsen K; Hansen HH
Neurosci Lett; 2011 Jan; 488(2):178-82. PubMed ID: 21087654
[TBL] [Abstract][Full Text] [Related]
38. The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.
Jensen MM; Lange SC; Thomsen MS; Hansen HH; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):339-42. PubMed ID: 21599837
[TBL] [Abstract][Full Text] [Related]
39. A mutually induced conformational fit underlies Ca
Archer CR; Enslow BT; Taylor AB; De la Rosa V; Bhattacharya A; Shapiro MS
J Biol Chem; 2019 Apr; 294(15):6094-6112. PubMed ID: 30808708
[TBL] [Abstract][Full Text] [Related]
40. Four drug-sensitive subunits are required for maximal effect of a voltage sensor-targeted KCNQ opener.
Wang AW; Yau MC; Wang CK; Sharmin N; Yang RY; Pless SA; Kurata HT
J Gen Physiol; 2018 Oct; 150(10):1432-1443. PubMed ID: 30166313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
